Advances in CAR Cell Therapies and Manufacturing

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 31 August 2026 | Viewed by 1596

Special Issue Editors


E-Mail Website
Guest Editor
Department of Chemical Engineering, Villanova University, Villanova, PA 19085, USA
Interests: upstream and downstream bio(pharmaceutical) processing, particularly for cell therapy products
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Genomic Medicine Unit CMC, Sanofi, Waltham, MA 01752, USA
Interests: microfluidics; microfabrication; soft lithography; mathematical modelling; lab on a chip; information analysis; single-cell analysis

Special Issue Information

Dear Colleagues,

This special issue will focus on CAR (Chimeric Antigen Receptor) cell therapies, highlighting recent advancements and manufacturing processes transforming cancer immunotherapy. The Issue will highlight new CAR types and important cell attributes such as the secretion of cytokines, granzymes etc.  Different gene delivery strategies will be considered for introducing the CAR transgene into target cells, including viral methods employing lentiviral vectors and non-viral methods with or without the use of (nano)particle vectors. The Issue will cover developments in genetic editing techniques, including strategies like the use of CRISPR/Cas9 for precise modifications and knocking out genes to enhance cell function and persistence. Addressing the inherent patient-to-patient variability in the quantity and quality of collected cells for autologous products is also a crucial challenge. This Issue will explore efficient methods for expanding and cryopreserving CAR cell products, optimizing cell yield and quality while minimizing cost. This includes discussions on optimizing the cell expansion step for optimal growth and differentiation, and exploring scale-up approaches for allogeneic products. Lastly, it will discuss essential biomarkers and assays for evaluating the safety, efficacy, and functionality of CAR cell products. This includes exploring critical quality attributes like transduction efficiency, viability, purity, and advancements in real-time monitoring and in-line quality control technologies.

Prof. Dr. William J. Kelly
Dr. Madhuresh C. Sumit
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • CAR cells
  • autologous
  • allogeneic
  • crispr
  • lentivirus
  • expansion
  • cryopreservation
  • isolation
  • biomarker
  • cytokines

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 1272 KB  
Review
Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering
by Benjamin J. L. Lim and John Maher
Cells 2026, 15(6), 494; https://doi.org/10.3390/cells15060494 - 10 Mar 2026
Viewed by 1193
Abstract
Adoptive immunotherapy using ex-vivo-amplified autologous αβ T cells has achieved notable success in the treatment of diverse cancer types. Pre-eminent among these developments has been the advent of chimeric antigen receptor (CAR) T cell therapy, which has revolutionised the treatment of selected haematological [...] Read more.
Adoptive immunotherapy using ex-vivo-amplified autologous αβ T cells has achieved notable success in the treatment of diverse cancer types. Pre-eminent among these developments has been the advent of chimeric antigen receptor (CAR) T cell therapy, which has revolutionised the treatment of selected haematological malignancies. However, autologous CAR T cell immunotherapy is poorly scalable and has demonstrated limited efficacy against solid tumours. Accordingly, there has been significant interest in alternative strategies that may bridge these gaps. The use of γδ T cells is an attractive alternative since they possess intrinsic anti-tumour activity and do not elicit graft versus host disease (GvHD) when employed as an allogeneic drug product. In this review, we evaluate the potential use of γδ T cells for cancer immunotherapy and how manufacturing and genetic engineering refinements can be used to potentiate this activity. We also summarise current clinical experience with CAR γδ T cell therapies and discuss the implications of these findings for the next generation of cellular immunotherapies. Full article
(This article belongs to the Special Issue Advances in CAR Cell Therapies and Manufacturing)
Show Figures

Figure 1

Back to TopTop